1 hr ago
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows...
Glenmark's first in class TRPA1 antagonist, GRC 17536, has shown positive data in a Phase 2a proof of concept study in patients with painful diabetic neuropathy Glenmark Pharmaceuticals today announced that its first in class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India. A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as detected by a standardized testing methodology.
Spain microvascular complications of diabetes market to report a dip...
Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth.
Gender differences in nerve regeneration after sciatic nerve injury...
In view of the global increase in diabetes, and the fact that recent findings indicate that diabetic neuropathy is more frequently seen in males, it is crucial to evaluate any gender differences in nerve regeneration in diabetes. Our aim was to evaluate in short-term experiments gender dissimilarities in axonal outgrowth in healthy and in genetically developed type 2 diabetic Goto-Kakizaki rats, and also to investigate the connection between activated and apoptotic Schwann cells after sciatic nerve injury and repair.
Lower Rate of Microvascular Complications in Statin Users Who Develop Diabetes
Among people newly diagnosed with diabetes, statin users appear less likely than nonusers to develop many diabetes-related microvascular complications, according to an observational study in the Lancet Diabetes & Endocrinology . Danish researchers studied more than 15,000 statin users who developed diabetes and 47,000 nonusers who developed diabetes.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Ring The NASDAQ Stock Market Opening Bell
BioDelivery Sciences International, Inc. , a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine, will visit the NASDAQ MarketSite in Times Square.
Diabetes Self Management
New Approach for Neuropathy Pain?
Pain from diabetic neuropathy can be debilitating for people who have the condition, and it can be difficult to treat, with only an estimated 40% to 60% of those affected achieving partial relief .